Two CAR-T cell therapy products targeting BCMA, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have received approval from the US FDA for treating relapsed/refractory multiple myeloma patients. Here, TNFRSF17 is linked to plasma cell myeloma.